Company Filing History:
Years Active: 2017
Title: The Innovations of Naresh Sharma: A Pioneer in Pharmaceutical Patenting
Introduction
Naresh Sharma is an accomplished inventor based in Gurgaon, India. He has made significant contributions to the field of pharmaceuticals, particularly with his innovative approach to antibiotic compositions. With a focus on purity and safety, Sharma's work has implications for the treatment of bacterial infections.
Latest Patents
Naresh Sharma holds a patent for his invention titled "Micronized Amoxicillin." This patent pertains to compositions of amoxicillin trihydrate that exhibit a unique surface area ranging from 1.0 to 2.5 mg. Notably, these compositions are free of organic contaminants such as dichloromethane, isopropanol, pivalic acid, and triethyl amine, achieving an impressive purity level between 97.0% and 99.99%. Additionally, his patent describes a method for preparing these compositions, underscoring their potential utility in treating bacterial infections.
Career Highlights
Currently, Naresh Sharma is affiliated with Dsm Sinochem Pharmaceuticals Netherlands B.V., where he continues to push the boundaries of pharmaceutical innovation. His career is marked by a strong commitment to creating safer and more effective medicinal solutions.
Collaborations
Throughout his career, Sharma has collaborated with talented individuals in the field, including his coworkers Rajinder Kapoor and Neeraj Tewari. These collaborations contribute to a rich environment of knowledge-sharing and innovation, enhancing the development of new solutions in pharmaceutical sciences.
Conclusion
Naresh Sharma exemplifies the kind of innovative spirit that drives advancements in the pharmaceutical industry. His patent on micronized amoxicillin not only highlights his ingenuity but also reflects a growing need for purity and effectiveness in treatments for bacterial infections. As he continues his work at Dsm Sinochem Pharmaceuticals, the implications of his inventions are sure to benefit both the medical community and patients globally.